Alnylam Pharmaceuticals, Inc. Stock Performance
as on January 3, 2026 at 2:29 am IST
Day's Low
Day's High
$396.08$407.22
0.99%
Downside
1.79%
Upside
52 Week's Low
52 Week's High
$205.87$495.5548.54%
Downside
23.87%
Upside
Alnylam Pharmaceuticals, Inc. share price movements today
- Previous Close
- $397.65
- Open
- $407.22
- Volume
- 569.6K
- Day's Low - High
- $396.08 - $407.22
- 52 Week Low - High
- $205.87 - $495.55
Alnylam Pharmaceuticals, Inc. Historical Returns
- 1 Month Return
- -12.65 %
- 3 Month Return
- -12.31 %
- 1 Year Return
- + 70.81 %
- 3 Year Return
- + 77.32 %
- 5 Year Return
- + 213.98 %
Alnylam Pharmaceuticals, Inc. Stock Fundamentals & Key Indicators
Check Alnylam Pharmaceuticals, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$52.5B
EPS (TTM)
4.9558
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
1242.66
Industry PE ratio
23.059253731343283
PEG Ratio
-0.49
EBITDA
-
Revenue (TTM)
-
Profit Margin
1.36%
Return On Equity TTM
32.72%
Alnylam Pharmaceuticals, Inc. Stock Valuation
Track how Alnylam Pharmaceuticals, Inc. P/E has moved over time to understand its valuation trends.
Alnylam Pharmaceuticals, Inc. in the last 5 years
Lowest (-115.71x)
September 30, 2024
Industry (23.06x)
January 5, 2026
Today (1242.66x)
January 5, 2026
Highest (185.95x)
December 31, 2025
Today’s Price to Earnings Ratio: 1242.66x
Alnylam Pharmaceuticals, Inc. vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Alnylam Pharmaceuticals, Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $52.5B | 213.98% | 1242.66 | 1.36% | |
| BUY | $37.8B | 429.51% | -16.34 | -264.83% | |
| BUY | $116.2B | 97.8% | 31.95 | 31.35% | |
| BUY | $81.8B | 60.58% | 18.48 | 32.13% |
Stock Returns calculator for Alnylam Pharmaceuticals, Inc. Stock including INR - Dollar returns
The Alnylam Pharmaceuticals, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Alnylam Pharmaceuticals, Inc. investment value today
Current value as on today
₹1,75,733
Returns
₹75,733
(+75.73%)
Returns from Alnylam Pharmaceuticals, Inc. Stock
₹70,757 (+70.76%)
Dollar Returns*
₹4,976 (+4.98%)
Analyst Recommendation on Alnylam Pharmaceuticals, Inc. Stock
Based on 34 analysts
70.59%
Buy
29.41%
Hold
0.00%
Sell
Based on 34 analysts, 70.59% of analysts recommend a 'BUY' rating for Alnylam Pharmaceuticals, Inc.. Average target price of $491.92
Alnylam Pharmaceuticals, Inc. Share Price Target
Get share price movements and forecasts by analysts on Alnylam Pharmaceuticals, Inc..
What analysts predicted
18.68%UPSIDE
Target Price
$491.92
Current Price
$400.05
Analyzed by
34 Analysts
Target
$491.92
Alnylam Pharmaceuticals, Inc. target price $491.92, a slight upside of 18.68% compared to current price of $400.05. According to 34 analysts rating.
Alnylam Pharmaceuticals, Inc. Stock’s Investor Sentiment and Interest
Search interest for Alnylam Pharmaceuticals, Inc. Stock has decreased by -23% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
Alnylam Pharmaceuticals, Inc. Quarterly Profit & Loss
All numbers in Millions USD
Alnylam Pharmaceuticals, Inc. Annual Profit & Loss
All numbers in Millions USD
Alnylam Pharmaceuticals, Inc. News & Key Events
Today's Timeline - 16 December
Tue, 05:34 PM
-Alnylam Pharmaceuticals enters a corrective phase after a strong run, declining over 20% from its recent peak.
Tue, 05:39 PM
-Alnylam Pharmaceuticals added to Nasdaq 100, seen as undervalued with a fair value estimate of $493.
Insights on Alnylam Pharmaceuticals, Inc.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Alnylam Pharmaceuticals, Inc. has shown a significant improvement in its net profit over the last two quarters. The net profit increased from -66.27 million dollars to 251.08 million dollars, reflecting an average growth of 126.4% per quarter.
- POSITIVE IMPACT
Revenue Rich
Alnylam Pharmaceuticals, Inc. has shown a positive revenue trend over the last five quarters, with revenue increasing from $500.91 million to $1.24 billion. This represents an average quarterly revenue growth of 19.3%, indicating consistent financial improvement for the company.
- POSITIVE IMPACT
Price Rise
In the last 1 year, ALNY stock has moved up by 70.8%
NO EFFECTAgainst Peers
In the last 1 year, Insmed Incorporated has given 153.5% return, outperforming this stock by 82.7%
- NO EFFECT
Against Peers
In the last 3 years, Insmed Incorporated has given 797.3% return, outperforming this stock by 720.0%
About Alnylam Pharmaceuticals, Inc.
| Organisation | Alnylam Pharmaceuticals, Inc. |
| Headquarters | 675 West Kendall Street, Cambridge, MA, United States, 02142 |
| Industry | Health Technology |
| CEO | Dr. Yvonne L. Greenstreet M.B.A., M.D. |
| E-voting on shares | Click here to vote |
Key Management of Alnylam Pharmaceuticals, Inc.
Name | Title |
|---|---|
Mr. Jeffrey V. Poulton M.B.A. | CFO & Executive VP |
Mr. Tolga Tanguler M.B.A. | Executive VP & Chief Commercial Officer |
Mr. Bryan Andrew Supran J.D. | Chief Legal Officer |
Ms. Christine Regan Akinc | Chief Corporate Communications Officer |
Dr. Yvonne L. Greenstreet M.B.A., M.D. | CEO & Director |
Dr. Phillip A. Sharp Ph.D. | Co-Founder, Member of the Scientific Advisory Board |
Mr. Timothy J. Maines | Chief Technical Operations & Quality Officer |
Mr. Piyush Sharma J.D. | Chief Ethics & Compliance Officer |
Dr. Kevin Joseph Fitzgerald Ph.D. | Executive VP, Chief Scientific Officer and Head of Early Research & Early Development |
Dr. Pushkal P. Garg M.D. | EVP of Development & Medical Affairs and Chief Research & Dev. Officer |
FAQs
What is Alnylam Pharmaceuticals, Inc. share price today?
Alnylam Pharmaceuticals, Inc. share price today is $400.05 as on at the close of the market. Alnylam Pharmaceuticals, Inc. share today touched a day high of $407.22 and a low of $396.08.
What is the 52 week high and 52 week low for Alnylam Pharmaceuticals, Inc. share?
Alnylam Pharmaceuticals, Inc. share touched a 52 week high of $495.55 on and a 52 week low of $205.87 on . Alnylam Pharmaceuticals, Inc. stock price today i.e. is closed at $400.05,which is 19.27% down from its 52 week high and 94.32% up from its 52 week low.
What is Alnylam Pharmaceuticals, Inc.'s market capitalisation today?
Alnylam Pharmaceuticals, Inc. market capitalisation is $0.05T as on .
How to invest in Alnylam Pharmaceuticals, Inc. Stock (ALNY) from India?
- Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
- Step 2: Search for Alnylam Pharmaceuticals, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Alnylam Pharmaceuticals, Inc. Shares that will get you 0.0037 shares as per Alnylam Pharmaceuticals, Inc. share price of $400.05 per share as on January 3, 2026 at 2:29 am IST.
What is the minimum amount required to buy Alnylam Pharmaceuticals, Inc. Stock (ALNY) from India?
Indian investors can start investing in Alnylam Pharmaceuticals, Inc. (ALNY) shares with as little as ₹89.975 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹899.75 in Alnylam Pharmaceuticals, Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Alnylam Pharmaceuticals, Inc. share’s latest price of $400.05 as on January 3, 2026 at 2:29 am IST, you will get 0.0250 shares of Alnylam Pharmaceuticals, Inc.. Learn more about
fractional shares .
What are the returns that Alnylam Pharmaceuticals, Inc. has given to Indian investors in the last 5 years?
Alnylam Pharmaceuticals, Inc. stock has given 213.98% share price returns and 23.11% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?